RA CAPITAL MANAGEMENT L.P. 13D and 13G filings for Vaxcyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 12,649,728 9.990% | 2,964,649 (+30.61%) | Filing |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 9,685,079 9.990% | 1,531,520 (+18.78%) | Filing |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 8,153,559 9.990% | 4,287,751 (+110.91%) | Filing |
| 2021-03-30 4:43 pm Purchase | 2021-03-24 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 3,865,808 7.530% | 155,109 (+4.18%) | Filing |
| 2021-02-16 4:39 pm Sale | 2020-12-31 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 3,710,699 7.300% | -1,778,482 (-32.40%) | Filing |
| 2020-07-10 4:33 pm Purchase | 2020-06-30 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 5,489,181 10.800% | 5,489,181 (New Position) | Filing |